Aaron Lorenzo

Most Signals Suggest A Positive 2007 For Biotech

Jan. 8, 2007

A number of signs point to some promising new and continuing trends for the biotech industry in the year ahead, observers are saying, with myriad financial opportunities available to companies and investors alike. (BioWorld Today)

HHS Doles Out $102.6M To BioCryst For Peramivir

Jan. 5, 2007

By Aaron Lorenzo

HHS Doles Out $102.6M To BioCryst For Peramivir

Jan. 5, 2007

By Aaron Lorenzo

FDA Signs Off On Poniard's Phase III Picoplatin Protocol

Jan. 4, 2007

By Aaron Lorenzo

FDA Signs Off On Poniard's Phase III Picoplatin Protocol

Jan. 4, 2007

By Aaron Lorenzo

MedImmune In-Licenses New Inflammatory Disease Target

Dec. 29, 2006

By Aaron Lorenzo

MedImmune Inc. acquired rights to a target for certain inflammatory diseases from Japan Tobacco (JT) Inc., with a lead compound the deal's centerpiece. (BioWorld Today)

NTD Funding Strategies Seek To Bring Bench Progress To Bedside

Dec. 29, 2006

By Anette Breindl and Aaron Lorenzo

MedImmune In-Licenses New Inflammatory Disease Target

Dec. 29, 2006

By Aaron Lorenzo

MedImmune Inc. acquired rights to a target for certain inflammatory diseases from Japan Tobacco (JT) Inc., with a lead compound the deal's centerpiece. (BioWorld Today)